Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

HCW9218 in Select Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05322408
Recruitment Status : Recruiting
First Posted : April 11, 2022
Last Update Posted : April 20, 2022
Sponsor:
Information provided by (Responsible Party):
Masonic Cancer Center, University of Minnesota

Brief Summary:
This is a single center, Phase I dose finding study of HCW9218 for the treatment of advanced/metastatic solid tumor cancer (except pancreatic and primary brain cancers). HCW9218 is a novel bi-functional fusion protein complex administered by subcutaneous (SC) injection. It is comprised of a soluble fusion of two human TGFβRII domains, human tissue factor, and human IL-15, and a second soluble fusion of two human TGFβRII domains and a sushi domain of human IL-15Rα. HCW9218 activates IL-15R signaling on effector immune cells and the dimeric TGFβRII functions as a "trap" for all three human TGF-β isoforms.

Condition or disease Intervention/treatment Phase
Solid Tumor Drug: HCW9218 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of HCW9218, a Bifunctional TGF-B; Antagonist/IL-15 Protein Complex, in Select Advanced Solid Tumors After Failing at Least Two Prior Therapies
Actual Study Start Date : April 1, 2022
Estimated Primary Completion Date : January 2027
Estimated Study Completion Date : January 2027

Arm Intervention/treatment
Experimental: Administer HCW9218

Administer HCW9218 as monotherapy at assigned dose by SC injection once every 3 weeks. Dose Level

-1 - 0.1 mg/kg

  1. - (start) 0.25 mg/kg
  2. - 0.5 mg/kg
  3. - 0.8 mg/kg
  4. - 1.2 mg/kg
Drug: HCW9218
HCW9218 at the assigned dose level is administered as a subcutaneous injection once every 3 weeks for a minimum of 2 treatment cycles unless medically contraindicated.
Other Name: Monotherapy




Primary Outcome Measures :
  1. The primary objective of the dose finding component is to determine the maximum tolerated dose (MTD) of HCW9218 [ Time Frame: through study completion, an average of 12 months ]
    Given that little to no toxicity is expected, the MTD will be determined using an adaptation of the continual reassessment method (CRM) (O'Quigley, 1996) starting with 1 patient cohorts.


Secondary Outcome Measures :
  1. Estimate response rate (complete response (CR), partial response (PR) or stable disease (SD) [ Time Frame: 3 months after 1st dose ]
    Response rate will be estimated by a simple proportion with 95% confidence limits if sufficient numbers exist

  2. Estimate response rate (complete response (CR), partial response (PR) or stable disease (SD) [ Time Frame: 6 months after 1st dose ]
    Response rate will be estimated by a simple proportion with 95% confidence limits if sufficient numbers exist

  3. Estimate response rate (complete response (CR), partial response (PR) or stable disease (SD) [ Time Frame: 12 months after 1st dose ]
    Response rate will be estimated by a simple proportion with 95% confidence limits if sufficient numbers exist

  4. Estimate progression of overall survival (OS) [ Time Frame: 6 months after 1st dose ]
    Estimated with Kaplan-Meier curves

  5. Estimate progression free survival (PFS) [ Time Frame: 6 months after 1st dose ]
    Estimated with Kaplan-Meier curves

  6. Estimate progression free survival (PFS) [ Time Frame: 1 year after 1st dose ]
    Estimated with Kaplan-Meier curves

  7. Estimate progression of overall survival (OS) [ Time Frame: 1 year after 1st dose ]
    Estimated with Kaplan-Meier curves



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically confirmed advanced/metastatic solid tumor cancer (except pancreatic and primary brain cancers), has failed at least 2 prior lines of therapy given either in the recurrent or metastatic setting and must be refractory to or intolerant of existing therapy(ies) known to provide clinical benefit for their condition.
  • Measurable disease per RECIST v 1.1.
  • Acute effects of any prior therapy must have resolved to baseline or Grade ≤1 NCI CTCAE v5 except for AEs not constituting a safety risk by enrolling Investigator judgment.
  • Age 18 years or older at the time of consent.
  • ECOG Performance Status 0 or 1.
  • Evidence of adequate organ function within 14 days prior to enrollment as defined in Section 4.1.6.
  • Adequate pulmonary function with PFTs >50% FEV1 if symptomatic or known impairment.
  • Sexually active persons of child-bearing potential or with partners of childbearing potential must agree to use a highly effective form of contraception (refer to Section 4.1.10 for acceptable methods) for at least 28 days after the last dose of HCW9218.
  • Provides voluntary written consent prior to the performance of any research related activity.

Exclusion Criteria:

  • Pregnant or breastfeeding.
  • History of clinically significant vascular disease, including any of the following within 6 months prior to start of study treatment: MI or unstable angina, percutaneous coronary intervention, bypass grafting, ventricular arrhythmia requiring medication, stroke or transient ischemic attack, symptomatic peripheral arterial disease.
  • Marked baseline prolongation of QT/QTc interval (e.g., demonstration of a QTc interval greater or equal to 470 milliseconds by Fridericia's correction).
  • Known or suspected untreated CNS metastases.
  • Anti-cancer treatment including surgery, radiotherapy, chemotherapy, other immunotherapy, or investigational therapy within 14 days before treatment start.
  • Other prior malignancy except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the subject is currently in complete remission, or any other cancer from which the subject has been disease-free for 3 years after surgical treatment.
  • Known hypersensitivity or history of allergic reactions attributed to compounds of similar chemical or biologic composition to the agents used in the study.
  • Prior therapy with TGF-β antagonist, IL-15 or analogs.
  • Concurrent use of St. John's wort and and/or other herbal CYP modulators within 7 days of Day 1. Must agree to not use during study treatment through the end of treatment visit to be eligible.
  • Known autoimmune disease requiring active treatment. Persons with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of enrollment. Inhaled or topical steroids, and adrenal replacement steroid doses ≤ 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
  • Active systemic infection requiring parenteral antibiotic therapy. All prior infections must have resolved following optimal therapy.
  • Prior organ allograft or allogeneic transplantation.
  • Known HIV-positive or AIDS.
  • Psychiatric illness/social situations that would limit compliance with study requirements.
  • Other illness or a medical issue that in the opinion of the Investigator would exclude the subject from participating in this study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05322408


Contacts
Layout table for location contacts
Contact: Cancer Center Info Nurse 612-624-2620 ccinfo@umn.edu

Locations
Layout table for location information
United States, Minnesota
Masonic Cancer Center - University of Minnesota Recruiting
Minneapolis, Minnesota, United States, 55455
Contact: Melissa Geller, MD    612-626-3111    gelle005@umn.edu   
Sponsors and Collaborators
Masonic Cancer Center, University of Minnesota
Investigators
Layout table for investigator information
Principal Investigator: Melissa Geller, MD Masonic Cancer Center, Univeristy of Minnesota
Layout table for additonal information
Responsible Party: Masonic Cancer Center, University of Minnesota
ClinicalTrials.gov Identifier: NCT05322408    
Other Study ID Numbers: 2021LS143
First Posted: April 11, 2022    Key Record Dates
Last Update Posted: April 20, 2022
Last Verified: April 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms